Lilly’s Foundayo Revenue Misses Wall Street Estimates by 19% in Q3
Eli Lilly reported $184 million in third-quarter revenue for its Foundayo weight-loss pill, 19% below Wall Street estimates. The once-daily pill is generally cheaper than injectable treatments.
By Alex JaninEli Lilly's weight-loss pill isn't taking off like Wall Street expected.Foundayo, a once-daily pill that's generally cheaper than injectables, missed Wall Street's estimates by 19% in the third quarter. The company reported $184 million in revenue for the drug, compared with $5.4 billi…